Immunotherapy with CTL peptide and VSSP eradicated established human papillomavirus (HPV) type 16 E7-expressing...

Area of Science:

• Oncology
• Immunology
• Vaccine Development

Background:

• Peptide-based vaccines for T-cell responses against tumors have faced clinical limitations.
• Novel adjuvants are crucial for improving vaccine efficacy.
• Ganglioside-containing very small size proteoliposomes (VSSP) represent a promising new adjuvant platform.

Purpose of the Study:

• To evaluate the efficacy of VSSP as an adjuvant in a preclinical model of human papillomavirus (HPV) 16-induced cervical cancer.
• To assess the ability of VSSP-adjuvanted peptide vaccines to induce anti-tumor immunity and regression of established tumors.

Main Methods:

• Development of VSSP by incorporating gangliosides into Neisseria meningitidis outer membrane protein complex.
• Vaccination of mice with a minimal cytotoxic T-lymphocyte (CTL) peptide derived from HPV 16 E7 protein formulated with VSSP.
• Tumor challenge and assessment of tumor growth, regression, and E7-specific CD8+ T-cell responses.

Main Results:

• Vaccination with HPV 16 E7 peptide and VSSP significantly protected mice against tumor challenge.
• Established tumors showed regression in response to the VSSP-adjuvanted vaccine.
• The vaccination induced robust E7-specific CD8+ T-cell responses.

Conclusions:

• VSSP is an effective adjuvant for peptide vaccines targeting HPV-induced tumors.
• VSSP-based vaccines hold potential for treating established cervical cancer by stimulating cellular immunity.
• This approach warrants further investigation for clinical translation in cancer immunotherapy.